Cybrexa Therapeutics has appointed John Houston, PhD, to its board of directors.
Dr. Houston brings more than 30 years of biotech and pharma drug development and management experience, including serving as the current CEO of Arvinas, Inc., a publicly traded targeted protein degradation biotech with programs in oncology and neuroscience. more